路透北京3月24日 - 中国“复星系”医药及疫苗巨头--复星医药600196.SS2196.HK周二公布，去年营收同比微升，净利润则大增逾两成；公司称创新驱动与国际化成效逐步显现，创新药品收入占比与境外收入占比的同步提升。
复星医药发布在上交所的财报称，2025年创新药品收入占制药业务收入比重、境外业务收入占营业收入比重双双提升至30%以上。
2025年营收同比增1.5%至416.7亿元
2025年净利润同比增21.7%至33.7亿元
拟每10股派发现金红利3.9元（税前）
2025年创新药品收入同比增长29.6%，占营收23.8%、占比同比提升5.16个百分点
2025年境外收入实现同比增长14.9%，占营收31.2%、占比同比提升3.64个百分点
此前称拟分拆所属子公司--疫苗业务平台复星安特金至香港联交所主板上市
复星医药A/H股周二收升2.1%和1.6%，今年迄今累跌8%和6.8%
（完）
(发稿 宿泱韫; 审校 田镧沁)
((jenny.su@thomsonreuters.com; 86-10-56692102;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.